1. J. L. Speyer, P. H. Sugarbaker, J. M. Collins, R. L. Dedrick, R. W. Klecker, Jr., and C. E. Myers. Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans.Cancer Res. 41:1916–1922 (1981).
2. M. Chadwick and J. Rogers. The physiological disposition of 5-fluorouracil in mice bearing solid L1210 lymphocytic leukemia.Cancer Res. 32:1045–1056 (1972).
3. B. G. Gustavsson, A. Brandberg, C. G. Regardh, and O. E. Almersjo. Regional and systemic serum concentration of 5-fluorouracil after portal and intravenous infusion: an experimental study in dogs.J. Pharmacokin. Biopharm. 7:665–673 (1979).
4. Y.-H. Kao, C.-Y. Yang, R. R. L. Chen, and J.-D. Huang. Pulmonary elimination of 5-fluorouracil in anesthetized rats.J. Pharm. Sci. 74:1095–1096 (1985).
5. J. G. Wagner, J. W. Gyves, P. L. Stetson, S. C. Walker-Andrews, I. S. Wollner, M. K. Cochran, and W. P. Ensminger. Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients.Cancer Res. 46:1499–1506 (1986).